TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32557923
Drug: Adenosine dosage
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine dosage of 175 μg/kg/min
Study: 32557923
Drug: Adenosine dosage
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine dosage of 210 μg/kg/min
Study: 32557923
Drug: Adenosine dosage
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine dosage of 140 μg/kg/min
Study: 32557923
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (210 μg/kg/min)
Study: 35729713
Drug: Ozoralizumab 30
Normalized name: benralizumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozoralizumab 30 mg plus MTX
Study: 35729713
Drug: Ozoralizumab 80
Normalized name: Ozoralizumab
DrugBank: Ozoralizumab (DB12014)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozoralizumab 80 mg plus MTX
Study: 38874739
Drug: Celecoxib 100
Normalized name: celecoxib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 100 mg BID
Study: 35973803
Drug: 1.5 million
Normalized name: colistin 1.5 million UNT Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 million IU/day of subcutaneous IL-2 (ILT-101) for 5 days followed by weekly injections for 12 weeks
Study: 35973803
Drug: 1.5 million
Normalized name: colistin 1.5 million UNT Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 million IU/day of subcutaneous IL-2 (ILT-101)
Study: 35714312
Drug: Enasidenib 100
Normalized name: enasidenib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enasidenib 100 mg/day
Study: 32379288
Drug: Facedown positioning
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facedown positioning for 8 hours daily for 5 days
Study: 32379288
Drug: Face forward
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face forward positioning for 8 hours daily for 5 days
Study: 33941193
Drug: Self-rated health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-rated health after reporting bodyweight (treatment group)
Study: 34262557
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (400 IU daily)
Study: 37780701
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonists (VKAs)
Study: 33879453
Drug: Sex hormone-binding
Normalized name: Testosterone bound to sex hormone-binding globulin (SHBG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex hormone-binding globulin (SHBG) levels (observational analysis)
Study: 35842106
Drug: Multifaceted clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted clinical pharmacy intervention (medication reconciliation at admission and discharge, medication review, patient/caregiver education, intensified communication with primary care providers, post-discharge follow-up including telepharmacology service)
Study: 33475710
Drug: Regular use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular use of aspirin
Study: 33475710
Drug: Regular use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular use of aspirin initiated before age 70 years
Study: 33475710
Drug: Regular use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular use of aspirin initiated at or after age 70 years
Study: 34108079
Drug: LX9211 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: LX9211 (single ascending dose)
Study: 34108079
Drug: LX9211 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: LX9211 (multiple ascending dose)
Study: 34108079
Drug: LX9211 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LX9211 (200 mg cohort)
Study: 36084153
Drug: Intralesional sodium
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intralesional sodium stibogluconate (SSG), administered weekly for a maximum of six doses.
Study: 33350325
Drug: Mebeverine 135
Normalized name: mebeverine 135 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebeverine 135 mg 3 times a day for 3 months
Study: 34582720
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg NEEM
Study: 34582720
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg NEEM
Study: 34582720
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg NEEM
Study: 34295981
Drug: Silymarin (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (140 mg)
Study: 32602592
Drug: Cognitive Evolutionary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Evolutionary Therapy (CET)
Study: 32005226
Drug: Having TB
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Having TB treatment supporter (TTS) during intensive phase of index TB case
Study: 36215222
Drug: Cod liver
Normalized name: Cod Liver Oil
DrugBank: Cod liver oil (DB11321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod liver oil (5 mL/day, 10 µg of vitamin D, n=17,278)
Study: 34155732
Drug: Intramuscular active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular active dose of morphine (0.15 mg/kg)
Study: 34155732
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low dose control (0.01 mg/kg)
Study: 32211679
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of mixed spices
Study: 32211679
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of mixed spices (no spices)
Study: 33530182
Drug: Intermittent cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent cervical traction combined with traditional Chinese medicine hot compress
Study: 35005585
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D supplementation (2800 IU/day) during pregnancy
Study: 35005585
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D sufficiency (≥ 75 nmol/l) at age 6 months
Study: 35005585
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D supplementation during pregnancy with vitamin D sufficiency at age 6 years
Study: 34658160
Drug: Combination Training
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Training (CT)
Study: 33451738
Drug: rAAV2/2‐ND4 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAAV2/2‐ND4 (single injection of 9 × 10^10 viral genomes in 90 μl)
Study: 36789634
Drug: Lopinavir/Ritonavir (200/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/Ritonavir (200/50 mg) under fasted conditions
Study: 36789634
Drug: Lopinavir/Ritonavir (200/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/Ritonavir (200/50 mg) under fed conditions
Study: 32286507
Drug: Old therapy
Normalized name: Deep Cold Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Old therapy
Study: 34059094
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg every 2 weeks) and ipilimumab (1 mg/kg every 6 weeks)
Study: 34059094
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg every 2 weeks) and ipilimumab (1 mg/kg every 6 weeks) with UV1 vaccine (8 intradermal injections during the first three months)
Study: 36068002
Drug: Intralesional collagenase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional collagenase Clostridium histolyticum (CCH) injections
Study: 36068002
Drug: Intralesional verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional verapamil (ILV) injections
Study: 33479386
Drug: Pioglitazone (PPAR-γ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (PPAR-γ agonist)
Study: 36013512
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate 50 mg/kg
Study: 36013512
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate 30 mg/kg
Study: 32192467
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate syrup (1 cc/Kg containing 5 mg/5 cc zinc sulfate)
Study: 32192467
Drug: Placebo syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup (1 cc/Kg sucrose)
Study: 34462887
Drug: HA-HL (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-HL (high and low molecular weight hyaluronic acid formulation)
Study: 35395276
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation (DE: 77Gy/35fx) to hypoxic volumes (HV)
Study: 34684481
Drug: Increased protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased protein intake to 1.7 g/kg body weight/d (New Zealand study, 10 weeks intervention)
Study: 34684481
Drug: Increased protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased protein intake to 1.54 g/kg body weight/d (Austrian study, 6 weeks intervention)
Study: 32386040
Drug: Myofascial trigger
Normalized name: Anti-AML/SCCL-trigger monoclonal antibody
DrugBank: pM-81 (DB17432)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial trigger point electroacupuncture therapy combined with solifenacin succinate
Study: 32474302
Drug: Intensive lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid-lowering therapy (pitavastatin + ezetimibe)
Study: 32773226
Drug: Standard lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard lipid-lowering therapy (pitavastatin monotherapy)
Study: 32212801
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg once daily for at least 7 days
Study: 32212801
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tab once daily for at least 7 days)
Study: 34687635
Drug: Apixaban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (5 mg twice daily or 2.5 mg twice daily)
Study: 34687635
Drug: Avoid anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoid anticoagulation (oral antiplatelet agents could be prescribed)
Study: 36475824
Drug: Flexible Assertive
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible Assertive Community Treatment (FACT)
Study: 36163929
Drug: Asciminib 80mg
DrugBank: Asciminib (DB12597)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Asciminib 80mg once daily (QD)
Study: 36163929
Drug: Investigator-selected TKI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator-selected TKI (imatinib, bosutinib, dasatinib, or nilotinib at their approved doses)
Study: 34039560
Drug: Treatment-resistant subretinal
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-resistant subretinal fluid (TR-SRF)
Study: 34032505
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (41 subjects)
Study: 34032505
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (39 subjects)
Study: 35641862
Drug: Ciprofloxacin oral
Normalized name: ciprofloxacin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin oral administration (500 mg) in morbidly obese individuals (n=10)
Study: 35641862
Drug: Ciprofloxacin intravenous
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin intravenous administration (400 mg) in morbidly obese individuals (n=10)
Study: 35641862
Drug: Ciprofloxacin oral
Normalized name: ciprofloxacin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin oral (500 mg) followed by intravenous (400 mg) administration in non-obese individuals (n=8)
Study: 35641862
Drug: Ciprofloxacin pharmacokinetics
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin pharmacokinetics in obese individuals
Study: 34663404
Drug: Avapritinib (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avapritinib (selective kinase inhibitor); administered daily
Study: 33928896
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention (MCI) consisting of child nutrition education plus family engagement through parental nutrition education, meal preparation and tasting
Study: 32524231
Drug: Low-dose milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose milk protein supplementation (10 g of milk protein daily)
Study: 32830553
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion during hyperglycemia
Study: 32474696
Drug: Local intra-gestational
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local intra-gestational sac methotrexate injection followed by dilation and curettage (D&C)
Study: 35793982
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (TA) 750 mg daily for a month after EVAR
Study: 33430774
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of a small amount of water immediately after recovery from general anesthesia.
Study: 32961681
Drug: Hippotherapy (30min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hippotherapy (30min sessions for 12 weeks, twice a week)
Study: 35086102
Drug: Chronic intranasal
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic intranasal oxytocin (OT) administered daily for 5 days or every other day
Study: 34553346
Drug: Fondaparinux 2.5mg
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5mg once daily for 4 to 6 weeks
Study: 34553346
Drug: Rivaroxaban 10mg
Normalized name: RIVAROXABAN 10MG TAB
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 10mg once daily
Study: 34553346
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (intermediate dose)
Study: 33313718
Drug: Pushing Splints
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pushing Splints 3 (PS3) therapy
Study: 33313718
Drug: Rapid maxillary
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid maxillary expansion and facemask therapy (RME/FM)
Study: 33112550
Drug: Colonic water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colonic water irrigation and oral antibiotics (metronidazole and ciprofloxacin)
Study: 32846108
Drug: Manual calculation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual calculation of insulin bolus (MC)
Study: 34889153
Drug: Turkish classical
Normalized name: Turkish Licorice Root
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turkish classical music therapy (6 sessions, 10 minutes each)
Study: 36739285
Drug: Aromatase Inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase Inhibitors (AI)
Study: 32070246
Drug: Levothyroxine (LT4)
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (LT4) supplementation (8 μg/kg birthweight/day as a single daily dose)
Study: 35411074
Drug: Psilocybin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin therapy (10 mg and 25 mg, orally administered, 7 days apart)
Study: 35411074
Drug: Psilocybin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin therapy (2 × 25 mg, orally administered, 3 weeks apart, plus 6 weeks of daily placebo)
Study: 35411074
Drug: Escitalopram (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (2 × 1 mg, orally administered, 3 weeks apart, plus 6 weeks of daily escitalopram 10–20 mg)
Study: 34933978
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (monthly home visits)
Study: 34618479
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted cognitive behavioral therapy (CA‐CBT)
Study: 34849429
Drug: Paracetamol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1000 mg in 150 ml normal saline)
Study: 34849429
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg in 150 ml normal saline)
Study: 32524424
Drug: Elevated efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elevated efavirenz concentration (≥ 4.0 mg/L)
Study: 33299890
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg per day)
Study: 32250057
Drug: Remimazolam (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam (single intravenous injection)
Study: 33032771
Drug: Intravenous golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous golimumab 2 mg/kg
Study: 32978200
Drug: Dabigatran 110
Normalized name: dabigatran 110 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 110 mg or 150 mg two times per day
Study: 32978200
Drug: Warfarin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin with international normalised ratio 2-3
Study: 35552386
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no LED treatment)
Study: 33408282
Drug: 2-hourly feeding
Normalized name: BAGS,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hourly feeding schedule
Study: 33408282
Drug: 3-hourly feeding
Normalized name: SYRINGE,FEEDING ENFIT 3ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-hourly feeding schedule
Study: 32041644
Drug: High-dose EAA/protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose EAA/protein composition (12.6g protein, 3.2g EAA per serving)
Study: 32041644
Drug: Low-dose EAA/protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose EAA/protein composition (6.3g protein, 1.6g EAA per serving)
Study: 34436509
Drug: Imatinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (400 mg/d) + standard of care (SOC: 40 mg dihydroartemisinin + 320 mg piperaquine/d)
Study: 34436509
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC: 40 mg dihydroartemisinin + 320 mg piperaquine/d)
Study: 34875022
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous iron
Study: 34875022
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous iron
Study: 33829920
Drug: Daily sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily sustained physical activity (PA)
Study: 32235773
Drug: Milk Protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk Protein Isolate (MPI) - 0.7 g protein/kg/d
Study: 32235773
Drug: Control (CON)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (CON) - 0.7 g carbohydrate/kg/d
Study: 33945886
Drug: Self-affirmation followed
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-affirmation followed by gain-framed health messages daily
Study: 33945886
Drug: Daily loss-framed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily loss-framed health messages only
Study: 34799275
Drug: Individualized follitropin
Normalized name: FOLLITROPIN
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Individualized follitropin delta dosing
Study: 33144049
Drug: PPAA (polaprezinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPAA (polaprezinc in polyacrylic acid solution)
Study: 35157493
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of BNT162b2 vaccine
Study: 34112656
Drug: Usual escalation
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual escalation (5 mg every 4 weeks)
Study: 34112656
Drug: Fast escalation
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast escalation (5 mg every 2 weeks)
Study: 32925765
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment (health education and Tiotropium bromide)
Study: 33225995
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly self-collected oral swabs (OS) regardless of symptoms
Study: 33225995
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly self-collected oral-nares swab (O-NS) regardless of symptoms
Study: 33225995
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly nurse collected nasopharyngeal swab (NPS) regardless of symptoms
Study: 33225995
Drug: Active daily
Normalized name: HOMOSALATE 3 mL in 100 mL / OCTINOXATE 8 mL in 100 mL / OXYBENZONE 2 mL in 100 mL TOPICAL LIQUID [GLAMTOX ACTIVE DAILY MOISTURIZING SUNSCREEN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active daily surveillance of symptoms and testing only in symptomatic participants (comparator group)
Study: 34667294
Drug: CVN058 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVN058 150 mg
Study: 34052211
Drug: RDN using
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDN using the Peregrine Kit with alcohol (0.6 mL per renal artery)
Study: 33135737
Drug: LEAP238-47 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEAP238-47 infusion in healthy human individuals (n=10)
Study: 36354718
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (100 mg adjunct testosterone, seven weekly injections)